As complement-targeted drug discovery continues to expand, researchers are placing greater emphasis on one critical question: how can complement biology be measured in a way that is truly relevant to disease mechanismsRead More…
For many years, complement was viewed mainly as a circulating “attack system” that tags microbes and punches holes in their membranes. A recent review in the Journal of Clinical Investigation reframes thisRead More…
The complement system is recognized as one of the mechanisms by which antibody drugs function. However, early antibody drug design efforts rarely focused on enhancing complement activation. As research has progressed, strategies toRead More…
Whether you’re studying autoimmune disorders, infectious disease models, tumor immunology, or neurodegeneration, C1q seems to show up in every figure legend, every mechanism diagram, and nearly every pathway conversation. So why isRead More…
Complement and Cancer In 2007, the first truly complement-targeted drug, the anti-C5 monoclonal antibody eculizumab (Eculizumab, Soliris), was approved for the treatment of PNH, and has achieved a revolutionary success, not onlyRead More…
The complement system has long been regarded as a fundamental component of innate immunity, with its three well-established activation routes—classical, lectin, and alternative pathways—serving as canonical pillars in immunology textbooks. However, aRead More…
Cancer is a complex, multifactorial disease that evolves through a series of functional capabilities, widely known as the hallmarks of cancer. Among the numerous biological systems influencing these hallmarks, the innate immuneRead More…
The complement system has long been recognized as a central player in innate immunity, defending the host against infections while maintaining tissue homeostasis. Among its components, complement C3 stands as a pivotalRead More…
Although complement was originally described as a powerful defense mechanism against invading pathogens, it can also be activated by tumor-targeting antibodies to kill tumor cells. Antibody and Complement Activation Immunoglobulin (Ig) inductionRead More…
Complement factor B (CFB) inhibitors exert therapeutic effects by specifically binding to factor B, inhibiting abnormal activation of the complement bypass pathway, and controlling intravascular and extravascular hemolysis in paroxysmal sleep hemoglobinuriaRead More…